

**Study Number:** MOG002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence**

**Test Compound:** 2-Hydroxy-4-methoxybenzophenone

**CAS Number:** 131-57-7

**Date Report Requested:** 12/13/2019

**Time Report Requested:** 13:27:38

**Lab:** RTI

**C Number:**

MOG002B

**Study Gender:**

Both

**PWG Approval Date**

See web page for date of PWG Approval

**Study Number:** MOG002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence**  
**Test Compound:** 2-Hydroxy-4-methoxybenzophenone  
**CAS Number:** 131-57-7

**Date Report Requested:** 12/13/2019  
**Time Report Requested:** 13:27:38  
**Lab:** RTI

	F0 Female				
	Treatment Groups (ppm)				
	0	3000	10000	30000	0.05 ppm EE
<b>Disposition Summary</b>					
Animals Initially In Study	25	25	25	25	25
Early Deaths					
Euthanized, moribund					1
Scheduled Deaths					
Scheduled sacrifice, terminal (GD 24, LD 4 - 28, SD 24 - 27)	25	25	25	25	24
Animals Examined Microscopically	1		1	7	1
ALIMENTARY SYSTEM					
LIVER	(0)	(0)	(0)	(0)	(1)
CARDIOVASCULAR SYSTEM					
No Tissues/Organs Examined					
ENDOCRINE SYSTEM					
ADRENAL GLANDS	(0)	(0)	(0)	(0)	(1)
GENERAL BODY SYSTEM					
No Tissues/Organs Examined					
GENITAL SYSTEM					
UTERUS	(0)	(0)	(1)	(4)	(0)
VAGINA	(0)	(0)	(0)	(2)	(0)
HEMATOLYMPHOID SYSTEM					
SPLEEN	(0)	(0)	(0)	(0)	(1)
INTEGUMENTARY SYSTEM					
MAMMARY GLANDS	(0)	(0)	(0)	(1)	(0)
MUSCULOSKELETAL SYSTEM					
No Tissues/Organs Examined					
NERVOUS SYSTEM					
No Tissues/Organs Examined					

**Study Number:** MOG002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence**  
**Test Compound:** 2-Hydroxy-4-methoxybenzophenone  
**CAS Number:** 131-57-7

**Date Report Requested:** 12/13/2019  
**Time Report Requested:** 13:27:38  
**Lab:** RTI

**F0 Female**

**Treatment Groups (ppm)**

**0**                      **3000**                      **10000**                      **30000**                      **0.05 ppm EE**

RESPIRATORY SYSTEM

No Tissues/Organs Examined

SPECIAL SENSES SYSTEM

No Tissues/Organs Examined

URINARY SYSTEM

	0	3000	10000	30000	0.05 ppm EE
KIDNEYS	(1)	(0)	(0)	(3)	(0)
CHRONIC PROGRESSIVE NEPHROPATHY	1 (100%)			1 (33%)	
RENAL TUBULE; DILATION				3 (100%)	
UROTHELIUM; HYPERPLASIA; FOCAL				2 (67%)	
INTERSTITIUM; BILATERAL; INFLAMMATION; FOCAL, CHRONIC ACTIVE				1 (33%)	
INTERSTITIUM; INFLAMMATION; CHRONIC ACTIVE				1 (33%)	
INTERSTITIUM; INFLAMMATION; CHRONIC ACTIVE (TOTAL)				2 (67%)	
PAPILLA; NECROSIS				1 (33%)	
RENAL TUBULE; EPITHELIUM; REGENERATION				2 (67%)	

Study Number: MOG002B  
 Test Type: MOG  
 Route: Dosing in Feed  
 Species/Strain: Rat/Sprague-Dawley

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence  
 Test Compound: 2-Hydroxy-4-methoxybenzophenone  
 CAS Number: 131-57-7

Date Report Requested: 12/13/2019  
 Time Report Requested: 13:27:38  
 Lab: RTI

	F1 Male: Prenatal Male				
	Treatment Groups (ppm)				
	0	3000	10000	30000	0.05 ppm EE
<b>Disposition Summary</b>					
Animals Initially In Study	23	20	22	20	15
Early Deaths					
Scheduled Deaths					
Scheduled sacrifice, terminal (PND 111 - 113)	23	20	22	20	15
Animals Examined Microscopically	5	1	2	15	1
Total number litters	5	1	2	15	1
ALIMENTARY SYSTEM					
LIVER	(2)	(0)	(0)	(1)	(0)
NECROSIS; DIFFUSE	1 (50%) [1]				
CARDIOVASCULAR SYSTEM					
No Tissues/Organs Examined					
ENDOCRINE SYSTEM					
No Tissues/Organs Examined					
GENERAL BODY SYSTEM					
No Tissues/Organs Examined					
GENITAL SYSTEM					
PENIS	(2)	(0)	(0)	(1)	(0)
HYPOSPADIAS				1 (100%) [1]	
PREPUTIAL GLANDS	(3)	(1)	(0)	(0)	(1)
DUCT; UNILATERAL; ECTASIA		1 (100%) [1]			
DUCT; ECTASIA	3 (100%) [3]				1 (100%) [1]
DUCT; ECTASIA (TOTAL)	3 (100%) [3]	1 (100%) [1]			1 (100%) [1]
INFLAMMATION; CHRONIC ACTIVE	1 (33%) [1]				
HEMATOLYMPHOID SYSTEM					
No Tissues/Organs Examined					

**Study Number:** MOG002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence**  
**Test Compound:** 2-Hydroxy-4-methoxybenzophenone  
**CAS Number:** 131-57-7

**Date Report Requested:** 12/13/2019  
**Time Report Requested:** 13:27:38  
**Lab:** RTI

---

**F1 Male: Prenatal Male**

---

**Treatment Groups (ppm)**

---

**0                      3000                      10000                      30000                      0.05 ppm EE**

---

INTEGUMENTARY SYSTEM  
No Tissues/Organs Examined

---

MUSCULOSKELETAL SYSTEM  
No Tissues/Organs Examined

---

NERVOUS SYSTEM  
No Tissues/Organs Examined

---

RESPIRATORY SYSTEM  
No Tissues/Organs Examined

---

SPECIAL SENSES SYSTEM  
No Tissues/Organs Examined

---

Study Number: MOG002B  
 Test Type: MOG  
 Route: Dosing in Feed  
 Species/Strain: Rat/Sprague-Dawley

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence  
 Test Compound: 2-Hydroxy-4-methoxybenzophenone  
 CAS Number: 131-57-7

Date Report Requested: 12/13/2019  
 Time Report Requested: 13:27:38  
 Lab: RTI

F1 Male: Prenatal Male

	Treatment Groups (ppm)				
	0	3000	10000	30000	0.05 ppm EE
URINARY SYSTEM					
KIDNEYS	(2)	(0)	(2)	(13)	(0)
UNILATERAL; CHRONIC PROGRESSIVE NEPHROPATHY				5 (38%) [5]	
CHRONIC PROGRESSIVE NEPHROPATHY	2 (100%) [2]			6 (46%) [6]	
CHRONIC PROGRESSIVE NEPHROPATHY (TOTAL)	2 (100%) [2]			11 (85%) [11]	
PELVIS; UNILATERAL; CONCRETION				2 (15%) [2]	
PELVIS; CONCRETION				5 (38%) [5]	
PELVIS; CONCRETION (TOTAL)				7 (54%) [7]	
RENAL TUBULE; CONCRETION				4 (31%) [4]	
RENAL TUBULE; CYST				1 (8%) [1]	
PELVIS; RIGHT; DILATION			2 (100%) [2]		
RENAL TUBULE; UNILATERAL; DILATION				5 (38%) [5]	
RENAL TUBULE; DILATION				7 (54%) [7]	
RENAL TUBULE; DILATION (TOTAL)				12 (92%) [12]	
PELVIS; HEMORRHAGE				1 (8%) [1]	
UROTHELIUM; HYPERPLASIA; DIFFUSE				4 (31%) [4]	
INFARCT				1 (8%) [1]	
INTERSTITIUM; UNILATERAL; INFLAMMATION; CHRONIC ACTIVE				2 (15%) [2]	
INTERSTITIUM; INFLAMMATION; CHRONIC ACTIVE				1 (8%) [1]	
INTERSTITIUM; INFLAMMATION; CHRONIC ACTIVE (TOTAL)				3 (23%) [3]	
PAPILLA; UNILATERAL; NECROSIS				1 (8%) [1]	
PAPILLA; NECROSIS				3 (23%) [3]	
PAPILLA; NECROSIS (TOTAL)				4 (31%) [4]	
RENAL TUBULE; EPITHELIUM; REGENERATION; UNILATERAL				2 (15%) [2]	
RENAL TUBULE; EPITHELIUM; REGENERATION				1 (8%) [1]	
RENAL TUBULE; EPITHELIUM; REGENERATION (TOTAL)				3 (23%) [3]	
UROTHELIUM; ULCER				2 (15%) [2]	
URINARY BLADDER	(2)	(0)	(0)	(9)	(0)

**Study Number:** MOG002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence**  
**Test Compound:** 2-Hydroxy-4-methoxybenzophenone  
**CAS Number:** 131-57-7

**Date Report Requested:** 12/13/2019  
**Time Report Requested:** 13:27:38  
**Lab:** RTI

**F1 Female: Prenatal Female**

**Treatment Groups (ppm)**

	0	3000	10000	30000	0.05 ppm EE
<b>Disposition Summary</b>					
Animals Initially In Study	22	20	22	20	15
Early Deaths					
Scheduled Deaths					
Scheduled sacrifice, terminal (GD 20 - 21, PND 109 - 123)	22	20	22	20	15
Animals Examined Microscopically		1			
Total number litters		1			
ALIMENTARY SYSTEM					
No Tissues/Organs Examined					
CARDIOVASCULAR SYSTEM					
No Tissues/Organs Examined					
ENDOCRINE SYSTEM					
No Tissues/Organs Examined					
GENERAL BODY SYSTEM					
No Tissues/Organs Examined					
GENITAL SYSTEM					
UTERUS	(0)	(1)	(0)	(0)	(0)
HEMATOLYMPHOID SYSTEM					
No Tissues/Organs Examined					
INTEGUMENTARY SYSTEM					
No Tissues/Organs Examined					
MUSCULOSKELETAL SYSTEM					
No Tissues/Organs Examined					
NERVOUS SYSTEM					
No Tissues/Organs Examined					

**Study Number:** MOG002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence**  
**Test Compound:** 2-Hydroxy-4-methoxybenzophenone  
**CAS Number:** 131-57-7

**Date Report Requested:** 12/13/2019  
**Time Report Requested:** 13:27:38  
**Lab:** RTI

---

**F1 Female: Prenatal Female**

---

**Treatment Groups (ppm)**

---

**0                      3000                      10000                      30000                      0.05 ppm EE**

---

**RESPIRATORY SYSTEM**

No Tissues/Organs Examined

---

**SPECIAL SENSES SYSTEM**

No Tissues/Organs Examined

---

**URINARY SYSTEM**

No Tissues/Organs Examined

---



Study Number: MOG002B  
 Test Type: MOG  
 Route: Dosing in Feed  
 Species/Strain: Rat/Sprague-Dawley

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence  
 Test Compound: 2-Hydroxy-4-methoxybenzophenone  
 CAS Number: 131-57-7

Date Report Requested: 12/13/2019  
 Time Report Requested: 13:27:38  
 Lab: RTI

F1 Male: Fertility Male

	Treatment Groups (ppm)				
	0	3000	10000	30000	0.05 ppm EE
<b>Disposition Summary</b>					
Animals Initially In Study	41	40	40	40	30
Early Deaths					
Scheduled Deaths					
Scheduled sacrifice, terminal (PND 153 - 155)	41	40	40	40	30
Animals Examined Microscopically	41	40	40	40	30
Total number litters	22	20	21	20	15
<b>ALIMENTARY SYSTEM</b>					
LIVER	(41)	(40)	(40)	(40)	(2)
HEPATODIAPHRAGMATIC NODULE			1 (3%) [1]	1 (3%) [1]	1 (50%) [1]
INFLAMMATION; FOCAL	3 (7%) [3]	10 (25%) [9]	8 (20%) [8]	3 (8%) [3]	
HEPATOCTE; NECROSIS; FOCAL	1 (2%) [1]				
MESENTERY	(0)	(0)	(0)	(1)	(0)
FAT; NECROSIS				1 (100%) [1]	
<b>CARDIOVASCULAR SYSTEM</b>					
No Tissues/Organs Examined					
<b>ENDOCRINE SYSTEM</b>					
ADRENAL GLANDS	(41)	(0)	(0)	(40)	(0)
CORTEX; VACUOLATION; DIFFUSE				3 (8%) [3]	
PITUITARY GLAND	(41)	(0)	(0)	(40)	(0)
RATHKES CLEFT; CYST; MULTILOCULAR	1 (2%) [1]				
THYROID GLANDS	(41)	(0)	(0)	(40)	(30)
FOLLICULAR CELL; HYPERTROPHY; DIFFUSE	1 (2%) [1]				
<b>GENERAL BODY SYSTEM</b>					
FAT	(0)	(0)	(0)	(0)	(1)
INFLAMMATION; CHRONIC ACTIVE					1 (100%) [1]
NECROSIS					1 (100%) [1]

Study Number: MOG002B  
 Test Type: MOG  
 Route: Dosing in Feed  
 Species/Strain: Rat/Sprague-Dawley

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence  
 Test Compound: 2-Hydroxy-4-methoxybenzophenone  
 CAS Number: 131-57-7

Date Report Requested: 12/13/2019  
 Time Report Requested: 13:27:38  
 Lab: RTI

F1 Male: Fertility Male

	Treatment Groups (ppm)				
	0	3000	10000	30000	0.05 ppm EE
GENITAL SYSTEM					
COAGULATING GLANDS	(41)	(0)	(0)	(40)	(0)
COWPERS GLANDS	(41)	(0)	(0)	(40)	(0)
DORSAL PROSTATE	(41)	(0)	(0)	(40)	(27)
EPIDIDYMIDES	(41)	(0)	(1)	(40)	(30)
LUMEN; GERM CELL; EXFOLIATED; UNILATERAL				1 (3%) [1]	
LUMEN; GERM CELL; EXFOLIATED			1 (100%) [1]		
LUMEN; GERM CELL; EXFOLIATED (TOTAL)			1 (100%) [1]	1 (3%) [1]	
LUMEN; UNILATERAL; HYOSPERMIA				1 (3%) [1]	
LUMEN; HYOSPERMIA			1 (100%) [1]		
LUMEN; HYOSPERMIA (TOTAL)			1 (100%) [1]	1 (3%) [1]	
LEVATOR ANI PLUS BULBOCAVERNOSUS MUSCLE	(41)	(0)	(0)	(40)	(0)
PREPUTIAL GLANDS	(41)	(5)	(4)	(40)	(5)
DUCT; ECTASIA	23 (56%) [18]	4 (80%) [3]	4 (100%) [4]	32 (80%) [19]	5 (100%) [4]
DUCT; FOREIGN MATERIAL					1 (20%) [1]
INFLAMMATION; CHRONIC ACTIVE	12 (29%) [9]	3 (60%) [2]	3 (75%) [3]	18 (45%) [14]	1 (20%) [1]
PROSTATE	(0)	(0)	(0)	(0)	(3)
INFILTRATION CELLULAR; MONONUCLEAR CELL					3 (100%) [3]
SEMINAL VESICLES	(41)	(0)	(0)	(40)	(0)
TESTES	(41)	(0)	(1)	(40)	(30)
GERMINAL EPITHELIUM; UNILATERAL; ATROPHY	2 (5%) [2]			1 (3%) [1]	
GERM CELL; UNILATERAL; DEGENERATION				1 (3%) [1]	
GERM CELL; DEGENERATION	2 (5%) [2]		1 (100%) [1]		
GERM CELL; DEGENERATION (TOTAL)	2 (5%) [2]		1 (100%) [1]	1 (3%) [1]	
VENTRAL PROSTATE	(41)	(0)	(0)	(40)	(27)
INTERSTITIUM; LYMPHOCYTE; INFILTRATION CELLULAR	8 (20%) [6]			6 (15%) [5]	

**Study Number:** MOG002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence**  
**Test Compound:** 2-Hydroxy-4-methoxybenzophenone  
**CAS Number:** 131-57-7

**Date Report Requested:** 12/13/2019  
**Time Report Requested:** 13:27:38  
**Lab:** RTI

**F1 Male: Fertility Male**

	Treatment Groups (ppm)				
	0	3000	10000	30000	0.05 ppm EE
<b>HEMATOLYMPHOID SYSTEM</b>					
SPLEEN	(2)	(1)	(0)	(0)	(0)
CONGESTION		1 (100%) [1]			
<b>INTEGUMENTARY SYSTEM</b>					
MAMMARY GLANDS	(1)	(0)	(0)	(0)	(0)
SKIN	(0)	(0)	(1)	(1)	(0)
HAIR FOLLICLE; ATROPHY; FOCAL				1 (100%) [1]	
EPIDERMIS; HYPERKERATOSIS; FOCAL				1 (100%) [1]	
EPIDERMIS; HYPERPLASIA; FOCAL				1 (100%) [1]	
DERMIS; INFLAMMATION; CHRONIC ACTIVE			1 (100%) [1]		
DERMIS; INFLAMMATION; CHRONIC ACTIVE (TOTAL)			1 (100%) [1]	1 (100%) [1]	
DERMIS; INFLAMMATION; CHRONIC ACTIVE, FOCAL				1 (100%) [1]	
EPIDERMIS; ULCERATION; FOCAL			1 (100%) [1]		
<b>MUSCULOSKELETAL SYSTEM</b>					
BONE	(2)	(0)	(1)	(0)	(0)
DEFORMITY			1 (100%) [1]		
<b>NERVOUS SYSTEM</b>					
No Tissues/Organs Examined					
<b>RESPIRATORY SYSTEM</b>					
No Tissues/Organs Examined					
<b>SPECIAL SENSES SYSTEM</b>					
No Tissues/Organs Examined					

Study Number: MOG002B  
 Test Type: MOG  
 Route: Dosing in Feed  
 Species/Strain: Rat/Sprague-Dawley

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence  
 Test Compound: 2-Hydroxy-4-methoxybenzophenone  
 CAS Number: 131-57-7

Date Report Requested: 12/13/2019  
 Time Report Requested: 13:27:38  
 Lab: RTI

F1 Male: Fertility Male

	Treatment Groups (ppm)				
	0	3000	10000	30000	0.05 ppm EE
URINARY SYSTEM					
KIDNEYS	(41)	(40)	(40)	(40)	(0)
CHRONIC PROGRESSIVE NEPHROPATHY	40 (98%) [22]	40 (100%) [20]	39 (98%) [21]	39 (98%) [20]	
PELVIS; CONCRETION				17 (43%) [13]	
RENAL TUBULE; CONCRETION				35 (88%) [19]	
UROTHELIUM; CONCRETION				1 (3%) [1]	
RENAL TUBULE; CYST			1 (3%) [1]		
PELVIS; RIGHT; DILATION	3 (7%) [3]		2 (5%) [2]	5 (13%) [5]	
RENAL TUBULE; DILATION				37 (93%) [20]	
UROTHELIUM; HYPERPLASIA; DIFFUSE				12 (30%) [10]	
UROTHELIUM; HYPERPLASIA; FOCAL		1 (3%) [1]		6 (15%) [6]	
UROTHELIUM; HYPERPLASIA (TOTAL)		1 (3%) [1]		18 (45%) [15]	
INFARCT	1 (2%) [1]				
INTERSTITIUM; INFLAMMATION; CHRONIC ACTIVE				22 (55%) [14]	
MEDULLA; INFLAMMATION; GRANULOMATOUS	1 (2%) [1]				
PAPILLA; NECROSIS				10 (25%) [10]	
UROTHELIUM; NECROSIS				1 (3%) [1]	
NEPHROBLASTEMATOSIS; FOCAL	1 (2%) [1]				
RENAL TUBULE; EPITHELIUM; REGENERATION				33 (83%) [17]	
UROTHELIUM; ULCER				12 (30%) [9]	
URINARY BLADDER	(2)	(0)	(0)	(17)	(0)
CONCRETION				11 (65%) [8]	
UROTHELIUM; EROSION; FOCAL				2 (12%) [2]	
UROTHELIUM; HYPERPLASIA; DIFFUSE				1 (6%) [1]	
SUBMUCOSA; INFLAMMATION; CHRONIC ACTIVE				1 (6%) [1]	

Study Number: MOG002B  
 Test Type: MOG  
 Route: Dosing in Feed  
 Species/Strain: Rat/Sprague-Dawley

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence  
 Test Compound: 2-Hydroxy-4-methoxybenzophenone  
 CAS Number: 131-57-7

Date Report Requested: 12/13/2019  
 Time Report Requested: 13:27:38  
 Lab: RTI

F1 Female: Fertility Female

Treatment Groups (ppm)

	0	3000	10000	30000	0.05 ppm EE
<b>Disposition Summary</b>					
Animals Initially In Study	41	40	40	40	30
Early Deaths					
Scheduled Deaths					
Scheduled sacrifice, terminal (GD 24, LD 28, PND 127 - 143)	41	40	40	40	30
Animals Examined Microscopically	35	37	33	32	28
Total number litters	22	20	20	20	15
<b>ALIMENTARY SYSTEM</b>					
LIVER	(35)	(2)	(1)	(32)	(0)
HEPATODIAPHRAGMATIC NODULE		2 (100%) [2]	1 (100%) [1]	4 (13%) [3]	
INFLAMMATION; FOCAL				2 (6%) [2]	
MESENTERY	(0)	(1)	(0)	(0)	(0)
FAT; NECROSIS		1 (100%) [1]			
PANCREAS	(2)	(0)	(0)	(1)	(0)
<b>CARDIOVASCULAR SYSTEM</b>					
No Tissues/Organs Examined					
<b>ENDOCRINE SYSTEM</b>					
ADRENAL GLANDS	(35)	(0)	(1)	(32)	(0)
UNILATERAL; CONGESTION; DIFFUSE			1 (100%) [1]		
CORTEX; HYPERTROPHY; FOCAL	1 (3%) [1]				
CORTEX; VACUOLATION; DIFFUSE				2 (6%) [2]	
PITUITARY GLAND	(35)	(0)	(0)	(32)	(0)
PARS DISTALIS; CYST	1 (3%) [1]				
THYROID GLANDS	(35)	(0)	(0)	(32)	(28)
FOLLICULAR CELL; HYPERTROPHY; DIFFUSE	1 (3%) [1]				
<b>GENERAL BODY SYSTEM</b>					
No Tissues/Organs Examined					

Study Number: MOG002B  
 Test Type: MOG  
 Route: Dosing in Feed  
 Species/Strain: Rat/Sprague-Dawley

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence  
 Test Compound: 2-Hydroxy-4-methoxybenzophenone  
 CAS Number: 131-57-7

Date Report Requested: 12/13/2019  
 Time Report Requested: 13:27:38  
 Lab: RTI

F1 Female: Fertility Female

	Treatment Groups (ppm)				
	0	3000	10000	30000	0.05 ppm EE
<b>GENITAL SYSTEM</b>					
CERVIX	(33)	(0)	(0)	(31)	(0)
CLITORAL GLANDS	(3)	(1)	(1)	(0)	(1)
DUCT; UNILATERAL; ECTASIA	1 (33%) [1]	1 (100%) [1]	1 (100%) [1]		1 (100%) [1]
DUCT; ECTASIA	2 (67%) [2]				
DUCT; ECTASIA (TOTAL)	3 (100%) [3]	1 (100%) [1]	1 (100%) [1]		1 (100%) [1]
INFLAMMATION, CHRONIC; ACTIVE	1 (33%) [1]				
OVARIES	(35)	(1)	(0)	(32)	(28)
CORPUS LUTEUM; CYST	3 (9%) [3]			2 (6%) [2]	1 (4%) [1]
FOLLICLE; CYST	3 (9%) [3]				
PERIOVARIAN; FAT; NECROSIS		1 (100%) [1]			
UTERUS	(35)	(0)	(0)	(32)	(0)
MUCOSA; DECIDUAL ALTERATION; FOCAL	1 (3%) [1]				
ENDOMETRIUM; HYPERPLASIA; CYSTIC	2 (6%) [2]				
VAGINA	(33)	(0)	(0)	(32)	(0)
EPITHELIUM; CYST	1 (3%) [1]			1 (3%) [1]	
<b>HEMATOLYMPHOID SYSTEM</b>					
LYMPH NODE, MANDIBULAR	(0)	(0)	(0)	(1)	(0)
CONGESTION				1 (100%) [1]	
LYMPHOCYTE; DEPLETION				1 (100%) [1]	
SPLEEN	(2)	(0)	(0)	(0)	(0)
RED PULP; PIGMENTED MACROPHAGE; INCREASED	1 (50%) [1]				
<b>INTEGUMENTARY SYSTEM</b>					
No Tissues/Organs Examined					
<b>MUSCULOSKELETAL SYSTEM</b>					
No Tissues/Organs Examined					

**Study Number:** MOG002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence**  
**Test Compound:** 2-Hydroxy-4-methoxybenzophenone  
**CAS Number:** 131-57-7

**Date Report Requested:** 12/13/2019  
**Time Report Requested:** 13:27:38  
**Lab:** RTI

---

**F1 Female: Fertility Female**

---

**Treatment Groups (ppm)**

---

**0                      3000                      10000                      30000                      0.05 ppm EE**

---

**NERVOUS SYSTEM**

No Tissues/Organs Examined

---

**RESPIRATORY SYSTEM**

No Tissues/Organs Examined

---

**SPECIAL SENSES SYSTEM**

No Tissues/Organs Examined

---

Study Number: MOG002B  
 Test Type: MOG  
 Route: Dosing in Feed  
 Species/Strain: Rat/Sprague-Dawley

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence  
 Test Compound: 2-Hydroxy-4-methoxybenzophenone  
 CAS Number: 131-57-7

Date Report Requested: 12/13/2019  
 Time Report Requested: 13:27:38  
 Lab: RTI

F1 Female: Fertility Female

	Treatment Groups (ppm)				
	0	3000	10000	30000	0.05 ppm EE
URINARY SYSTEM					
KIDNEYS	(35)	(37)	(33)	(32)	(0)
CHRONIC PROGRESSIVE NEPHROPATHY	18 (51%) [14]	35 (95%) [19]	29 (88%) [19]	22 (69%) [17]	
PELVIS; CONCRETION				9 (28%) [5]	
RENAL TUBULE; CONCRETION				13 (41%) [12]	
RENAL TUBULE; CYST			3 (9%) [3]	1 (3%) [1]	
RENAL TUBULE; EPITHELIUM; DEGENERATION				21 (66%) [14]	
PELVIS; LEFT; DILATION				1 (3%) [1]	
PELVIS; RIGHT; DILATION		1 (3%) [1]		4 (13%) [4]	
PELVIS; DILATION (TOTAL)		1 (3%) [1]		5 (16%) [5]	
RENAL TUBULE; DILATION				28 (88%) [19]	
CAPSULE; FIBROSIS				1 (3%) [1]	
UROTHELIUM; HYPERPLASIA; DIFFUSE				15 (47%) [12]	
INTERSTITIUM; INFLAMMATION; CHRONIC ACTIVE				8 (25%) [8]	
UROTHELIUM; METAPLASIA; SQUAMOUS				1 (3%) [1]	
MINERALIZATION	9 (26%) [8]	28 (76%) [17]	24 (73%) [18]	10 (31%) [8]	
PAPILLA; NECROSIS				4 (13%) [3]	
NEPHROBLASTEMATOSIS; FOCAL		2 (5%) [2]			
RENAL TUBULE; EPITHELIUM; REGENERATION			3 (9%) [3]	13 (41%) [12]	
UROTHELIUM; ULCER				6 (19%) [6]	
URETERS	(1)	(0)	(0)	(1)	(0)
UROTHELIUM; HYPERPLASIA; DIFFUSE				1 (100%) [1]	
URINARY BLADDER	(0)	(0)	(0)	(1)	(0)
CONCRETION				1 (100%) [1]	
LUMEN; DILATION				1 (100%) [1]	
UROTHELIUM; HYPERPLASIA; FOCAL				1 (100%) [1]	



Study Number: MOG002B  
 Test Type: MOG  
 Route: Dosing in Feed  
 Species/Strain: Rat/Sprague-Dawley

PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence  
 Test Compound: 2-Hydroxy-4-methoxybenzophenone  
 CAS Number: 131-57-7

Date Report Requested: 12/13/2019  
 Time Report Requested: 13:27:38  
 Lab: RTI

	F2 Male				
	Treatment Groups (ppm)				
	0	3000	10000	30000	0.05 ppm EE
<b>Disposition Summary</b>					
Animals Initially In Study	91	110	101	88	87
Early Deaths					
Scheduled Deaths					
Scheduled sacrifice, terminal (PND 28)	91	110	101	88	87
Animals Examined Microscopically	6	5	6	6	4
Total number litters	3	4	6	6	4
ALIMENTARY SYSTEM					
LIVER	(0)	(1)	(0)	(0)	(0)
CONGESTION; DIFFUSE		1 (100%) [1]			
CARDIOVASCULAR SYSTEM					
No Tissues/Organs Examined					
ENDOCRINE SYSTEM					
No Tissues/Organs Examined					
GENERAL BODY SYSTEM					
No Tissues/Organs Examined					
GENITAL SYSTEM					
TESTES	(2)	(4)	(3)	(3)	(2)
SEMIFEROUS TUBULE; BILATERAL; DEGENERATION					1 (50%) [1]
SEMIFEROUS TUBULE; LEFT; DEGENERATION		3 (75%) [3]			
SEMIFEROUS TUBULE; RIGHT; DEGENERATION					1 (50%) [1]
SEMIFEROUS TUBULE; DEGENERATION (TOTAL)		3 (75%) [3]			2 (100%) [2]
BILATERAL; RETENTION		1 (25%) [1]		1 (33%) [1]	
LEFT; RETENTION			2 (67%) [2]		
RIGHT; RETENTION			1 (33%) [1]	1 (33%) [1]	
RETENTION (TOTAL)		1 (25%) [1]	3 (100%) [3]	2 (67%) [2]	

**Study Number:** MOG002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence**  
**Test Compound:** 2-Hydroxy-4-methoxybenzophenone  
**CAS Number:** 131-57-7

**Date Report Requested:** 12/13/2019  
**Time Report Requested:** 13:27:38  
**Lab:** RTI

	F2 Male				
	Treatment Groups (ppm)				
	0	3000	10000	30000	0.05 ppm EE
HEMATOLYMPHOID SYSTEM					
No Tissues/Organs Examined					
INTEGUMENTARY SYSTEM					
No Tissues/Organs Examined					
MUSCULOSKELETAL SYSTEM					
DIAPHRAGM	(0)	(0)	(0)	(3)	(1)
LIMB	(3)	(0)	(0)	(0)	(0)
DEFORMITY	1 (33%) [1]				
NERVOUS SYSTEM					
No Tissues/Organs Examined					
RESPIRATORY SYSTEM					
No Tissues/Organs Examined					
SPECIAL SENSES SYSTEM					
No Tissues/Organs Examined					
URINARY SYSTEM					
KIDNEYS	(3)	(0)	(3)	(0)	(1)
LEFT; CONGESTION; DIFFUSE	1 (33%) [1]				
PELVIS; RIGHT; DILATION	2 (67%) [2]				
PAPILLA; MINERALIZATION; FOCAL	1 (100%) [1]				

**Study Number:** MOG002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence**  
**Test Compound:** 2-Hydroxy-4-methoxybenzophenone  
**CAS Number:** 131-57-7

**Date Report Requested:** 12/13/2019  
**Time Report Requested:** 13:27:38  
**Lab:** RTI

	F2 Female				
	Treatment Groups (ppm)				
	0	3000	10000	30000	0.05 ppm EE
<b>Disposition Summary</b>					
Animals Initially In Study	94	95	85	86	91
Early Deaths					
Scheduled Deaths					
Scheduled sacrifice, terminal (PND 28)	94	95	85	86	91
Animals Examined Microscopically	4	2		8	2
Total number litters	2	2		5	2
ALIMENTARY SYSTEM					
No Tissues/Organs Examined					
CARDIOVASCULAR SYSTEM					
No Tissues/Organs Examined					
ENDOCRINE SYSTEM					
No Tissues/Organs Examined					
GENERAL BODY SYSTEM					
No Tissues/Organs Examined					
GENITAL SYSTEM					
No Tissues/Organs Examined					
HEMATOLYMPHOID SYSTEM					
No Tissues/Organs Examined					
INTEGUMENTARY SYSTEM					
No Tissues/Organs Examined					
MUSCULOSKELETAL SYSTEM					
LIMB	(3)	(0)	(0)	(0)	(1)
DEFORMITY	1 (33%) [1]				1 (100%) [1]
NERVOUS SYSTEM					
No Tissues/Organs Examined					

**Study Number:** MOG002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence**  
**Test Compound:** 2-Hydroxy-4-methoxybenzophenone  
**CAS Number:** 131-57-7

**Date Report Requested:** 12/13/2019  
**Time Report Requested:** 13:27:38  
**Lab:** RTI

F2 Female					
	Treatment Groups (ppm)				
	0	3000	10000	30000	0.05 ppm EE
RESPIRATORY SYSTEM					
No Tissues/Organs Examined					
SPECIAL SENSES SYSTEM					
EYES	(0)	(1)	(0)	(0)	(0)
URINARY SYSTEM					
KIDNEYS	(1)	(1)	(0)	(7)	(1)
PELVIS; LEFT; DILATION				3 (43%) [2]	
PELVIS; RIGHT; DILATION				3 (43%) [3]	
PELVIS; DILATION (TOTAL)				6 (86%) [3]	
RENAL TUBULE; DILATION				4 (57%) [3]	
URINARY BLADDER	(0)	(0)	(0)	(2)	(0)
CONCRETION				1 (50%) [1]	
HEMORRHAGE				1 (50%) [1]	
UROTHELIUM; INFLAMMATION; CHRONIC ACTIVE				1 (50%) [1]	
UROTHELIUM; ULCERATION; FOCAL				1 (50%) [1]	

**Study Number:** MOG002B  
**Test Type:** MOG  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Sprague-Dawley

**PA03R: Non-Neoplastic Lesion Summary with Percent and Litter Incidence**  
**Test Compound:** 2-Hydroxy-4-methoxybenzophenone  
**CAS Number:** 131-57-7

**Date Report Requested:** 12/13/2019  
**Time Report Requested:** 13:27:38  
**Lab:** RTI

#### LEGEND

---

Number of animals examined given for each tissue. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion.

Number of animals with observation reported with percent incidence in parentheses

Number of litters with observations shown in square brackets for F1 and F2 animals. F1 litter incidence based on the number of F0 dams; F2 litter incidence based on number of F1 dams.

Phase day range of terminal sacrifice shown in parentheses in disposition summary

SD – Study Day; GD – Gestation Day; LD – Lactation Day; PND – Postnatal Day, adults post-weaning

EE = Ethinyl estradiol

**\*\* END OF REPORT \*\***